Pathogenicity and immunogenicity of attenuated, nef -deleted HIV-1 strains in vivo

详细信息    查看全文

• 作者：Paul R Gorry (1) (2) (3)
  Dale A McPhee (2) (4) (6)
  Erin Verity (1) (4) (6)
  Wayne B Dyer (7) (8)
  Steven L Wesselingh (1) (2) (3)
  Jennifer Learmont (7)
  John S Sullivan (7) (8)
  Michael Roche (1)
  John J Zaunders (9)
  Dana Gabuzda (11) (12)
  Suzanne M Crowe (1) (3)
  John Mills (3) (4) (5)
  Sharon R Lewin (13) (3)
  Bruce J Brew (10)
  Anthony L Cunningham (14)
  Melissa J Churchill (1)
  
• 刊名：Retrovirology
• 出版年：2007
• 出版时间：December 2007
• 年：2007
• 卷：4
• 期：1
• 全文大小：622KB
• 参考文献：1. Duerr A, Wasserheit JN, Corey L: HIV vaccines: new frontiers in vaccine development. / Clin Infect Dis 2006, 43 (4) : 500鈥?11. CrossRef
  2. Letvin NL: Progress and obstacles in the development of an AIDS vaccine. / Nat Rev Immunol 2006, 6 (12) : 930鈥?39. CrossRef
  3. McMichael AJ: HIV vaccines. / Annu Rev Immunol 2006, 24: 227鈥?55. CrossRef
  4. Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. / PLoS Med 2006, 3 (11) : e442. CrossRef
  5. Chinen J, Shearer WT: Molecular virology and immunology of HIV infection. / J Allergy Clin Immunol 2002, 110 (2) : 189鈥?98. CrossRef
  6. Letvin NL, Walker BD: Immunopathogenesis and immunotherapy in AIDS virus infections. / Nat Med 2003, 9 (7) : 861鈥?66. CrossRef
  7. Spearman P: Current progress in the development of HIV vaccines. / Curr Pharm Des 2006, 12 (9) : 1147鈥?167. CrossRef
  8. McMichael AJ, Hanke T: HIV vaccines 1983鈥?003. / Nat Med 2003, 9 (7) : 874鈥?80. CrossRef
  9. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. / J Infect Dis 2005, 191 (5) : 654鈥?65. CrossRef
  10. Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M: HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. / J Infect Dis 2005, 192 (6) : 974鈥?83. CrossRef
  11. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW: Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. / J Infect Dis 2005, 191 (5) : 666鈥?77. CrossRef
  12. Graham BS, Mascola JR: Lessons from failure--preparing for future HIV-1 vaccine efficacy trials. / J Infect Dis 2005, 191 (5) : 647鈥?49. CrossRef
  13. Pantaleo G, Koup RA: Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. / Nat Med 2004, 10 (8) : 806鈥?10. CrossRef
  14. Whitney JB, Ruprecht RM: Live attenuated HIV vaccines: pitfalls and prospects. / Curr Opin Infect Dis 2004, 17 (1) : 17鈥?6. CrossRef
  15. Singh M: No vaccine against HIV yet--are we not perfectly equipped? / Virol J 2006, 3: 60. CrossRef
  16. Klase Z, Donio MJ, Blauvelt A, Marx PA, Jeang KT, Smith SM: A peptide-loaded dendritic cell based cytotoxic T-lymphocyte (CTL) vaccination strategy using peptides that span SIV Tat, Rev, and Env overlapping reading frames. / Retrovirology 2006, 3: 1. CrossRef
  17. Mosca JD, Chang YN, Williams G: Antigen-presenting particle technology using inactivated surface-engineered viruses: induction of immune responses against infectious agents. / Retrovirology 2007, 4: 32. CrossRef
  18. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Desrosiers RC: Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. / J Virol 1999, 73 (10) : 8356鈥?363.
  19. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC: Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. / J Virol 1996, 70 (6) : 3724鈥?733.
  20. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. / Science 1992, 258 (5090) : 1938鈥?941. CrossRef
  21. Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ: Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. / Lancet 1995, 345 (8961) : 1342鈥?344. CrossRef
  22. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, Ruprecht RM: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. / Nat Med 2000, 6 (2) : 200鈥?06. CrossRef
  23. Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, Montefiori DC, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM: Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. / J Infect Dis 2004, 189 (12) : 2167鈥?173. CrossRef
  24. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL: Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. / J Virol 1999, 73 (5) : 4009鈥?018.
  25. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. / Nat Med 2000, 6 (2) : 207鈥?10. CrossRef
  26. Sawai ET, Hamza MS, Ye M, Shaw KE, Luciw PA: Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef. / J Virol 2000, 74 (4) : 2038鈥?045. CrossRef
  27. Hofmann-Lehmann R, Vlasak J, Williams AL, Chenine AL, McClure HM, Anderson DC, O'Neil S, Ruprecht RM: Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. / Aids 2003, 17 (2) : 157鈥?66. CrossRef
  28. Churchill M, Sterjovski J, Gray L, Cowley D, Chatfield C, Learmont J, Sullivan JS, Crowe SM, Mills J, Brew BJ, Wesselingh SL, McPhee DA, Gorry PR: Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. / J Infect Dis 2004, 190 (12) : 2181鈥?186. CrossRef
  29. Churchill MJ, Rhodes DI, Learmont JC, Sullivan JS, Wesselingh SL, Cooke IR, Deacon NJ, Gorry PR: Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source. / J Virol 2006, 80 (2) : 1047鈥?052. CrossRef
  30. Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS: Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. / N Engl J Med 1999, 340 (22) : 1715鈥?722. CrossRef
  31. Birch MR, Learmont JC, Dyer WB, Deacon NJ, Zaunders JJ, Saksena N, Cunningham AL, Mills J, Sullivan JS: An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). / J Clin Virol 2001, 22 (3) : 263鈥?70. CrossRef
  32. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, Lawson VA, Crowe S, Maertz S, Sonza S, Learmont J, Sullivan JS, Cunningham A, Dwyer D, Dowton D, Mills J: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. / Science 1995, 270 (5238) : 988鈥?91. CrossRef
  33. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC: Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. / N Engl J Med 1995, 332 (4) : 228鈥?32. CrossRef
  34. Kondo M, Shima T, Nishizawa M, Sudo K, Iwamuro S, Okabe T, Takebe Y, Imai M: Identification of attenuated variants of HIV-1 circulating recombinant form 01_AE that are associated with slow disease progression due to gross genetic alterations in the nef/long terminal repeat sequences. / Journal of Infectious Diseases 2005, 192: 56鈥?1. CrossRef
  35. Mariani R, Kirchhoff F, Greenough TC, Sullivan JL, Desrosiers RC, Skowronski J: High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. / J Virol 1996, 70 (11) : 7752鈥?764.
  36. Rhodes DI, Ashton L, Solomon A, Carr A, Cooper D, Kaldor J, Deacon N: Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group. / J Virol 2000, 74 (22) : 10581鈥?0588. CrossRef
  37. Salvi R, Garbuglia AR, Di Caro A, Pulciani S, Montella F, Benedetto A: Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor. / J Virol 1998, 72 (5) : 3646鈥?657.
  38. Learmont J, Tindall B, Evans L, Cunningham A, Cunningham P, Wells J, Penny R, Kaldor J, Cooper DA: Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. / Lancet 1992, 340 (8824) : 863鈥?67. CrossRef
  39. Gorry PR, Churchill M, Learmont J, Cherry C, Dyer WB, Wesselingh SL, Sullivan JS: Replication-dependent pathogenicity of attenuated, nef-deleted HIV-1 in vivo. / Journal of Acquired Immune Deficiency Syndromes 2007, In press..
  40. Verity E, Zotos D, Wilson K, Chatfield C, Lawson VA, Dwyer D, Cunningham A, Learmont J, Dyer W, Sullivan J, Churchill M, Wesselingh SL, Gabuzda D, Gorry PR, McPhee D: Viral phenotypes and antibody responses in long term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef/long terminal repeat region. / J Virol 2007, 81: 9268鈥?278. CrossRef
  41. Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, Birch CJ, Bell JE, Bannert N, Crawford K, Wang H, Schols D, De Clercq E, Kunstman K, Wolinsky SM, Gabuzda D: Macrophage Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and Lymphoid Tissues Predicts Neurotropism Independent of Coreceptor Specificity. / J Virol 2001, 75 (21) : 10073鈥?0089. CrossRef
  42. Rhodes D, Solomon A, Bolton W, Wood J, Sullivan J, Learmont J, Deacon N: Identification of a new recipient in the Sydney Blood Bank Cohort: a long-term HIV type 1-infected seroindeterminate individual. / AIDS Res Hum Retroviruses 1999, 15 (16) : 1433鈥?439. CrossRef
  43. Etemad-Moghadam B, Sun Y, Nicholson EK, Fernandes M, Liou K, Gomila R, Lee J, Sodroski J: Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. / J Virol 2000, 74 (9) : 4433鈥?440. CrossRef
  44. Gray L, Sterjovski J, Churchill M, Ellery P, Nasr N, Lewin SR, Crowe SM, Wesselingh S, Cunningham AL, Gorry PR: Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. / Virology 2005, 337: 384鈥?98. CrossRef
  45. Crowe SM, Ho DD, Marriott D, Brew B, Gorry PR, Sullivan JS, Learmont J, Mills J: In vivo replication kinetics of a nef-deleted strain of HIV-1. / Aids 2005, 19 (8) : 842鈥?43. CrossRef
  46. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD: Decay characteristics of HIV-1-infected compartments during combination therapy. / Nature 1997, 387 (6629) : 188鈥?91. CrossRef
  47. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. / Science 1996, 271 (5255) : 1582鈥?586. CrossRef
  48. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, / et al.: Viral dynamics in human immunodeficiency virus type 1 infection. / Nature 1995, 373 (6510) : 117鈥?22. CrossRef
  49. Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, Spear G, Heath-Chiozzi M, Rousseau F, Fox L, Spritzler J, Leonard JM, Lederman MM: Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. / J Infect Dis 1999, 179 (4) : 799鈥?07. CrossRef
  50. Gray L, Churchill MJ, Sterjovski J, Witlox K, Learmont J, Sullivan JS, Wesselingh SL, Gabuzda D, Cunningham AL, McPhee DA, Gorry PR: Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long term survivors infected from a single source. / Virology Journal 2007, 4: 75. CrossRef
  51. Jekle A, Schramm B, Jayakumar P, Trautner V, Schols D, De Clercq E, Mills J, Crowe SM, Goldsmith MA: Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. / J Virol 2002, 76 (14) : 6966鈥?973. CrossRef
  52. Gorry PR, McPhee DA, Wesselingh SL, Churchill MJ: Macrophage tropism and cytopathicity of HIV-1 variants isolated sequentially from a long-term survivor infected with nef-deleted virus. / The Open Microbiology Journal 2007, 1: 1鈥?.
  53. Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, Cayabyab M, Farzan M, Wang H, Bell JE, Kunstman K, Moore JP, Wolinsky SM, Gabuzda D: Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. / Journal of Virology 2002, 76 (12) : 6277鈥?292. CrossRef
  54. Ohagen A, Ghosh S, He J, Huang K, Chen Y, Yuan M, Osathanondh R, Gartner S, Shi B, Shaw G, Gabuzda D: Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: evidence for a role of the envelope. / Journal of Virology 1999, 73 (2) : 897鈥?06.
  55. Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J, Simmonds P, Clapham PR: Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. / J Virol 2004, 78 (13) : 6915鈥?926. CrossRef
  56. Zaunders JJ, Geczy AF, Dyer WB, McIntyre LB, Cooley MA, Ashton LJ, Raynes-Greenow CH, Learmont J, Cooper DA, Sullivan JS: Effect of long-term infection with nef-defective attenuated HIV type 1 on CD4+ and CD8+ T lymphocytes: increased CD45RO+CD4+ T lymphocytes and limited activation of CD8+ T lymphocytes. / AIDS Res Hum Retroviruses 1999, 15 (17) : 1519鈥?527. CrossRef
  57. Chun TW, Chadwick K, Margolick J, Siliciano RF: Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI. / J Virol 1997, 71 (6) : 4436鈥?444.
  58. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C: Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. / Science 1999, 284 (5415) : 816鈥?19. CrossRef
  59. Lapenta C, Parlato S, Spada M, Santini SM, Rizza P, Logozzi M, Proietti E, Belardelli F, Fais S: Human lymphoblastoid CD4(+) T cells become permissive to macrophage-tropic strains of human immunodeficiency virus type 1 after passage into severe combined immunodeficient mice through in vivo upregulation of CCR5: in vivo dynamics of CD4(+) T-cell differentiation in pathogenesis of AIDS. / J Virol 1998, 72 (12) : 10323鈥?0327.
  60. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, Fauci AS: Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. / Proc Natl Acad Sci U S A 1990, 87 (16) : 6058鈥?062. CrossRef
  61. Kelleher AD, Zaunders JJ: Decimated or missing in action: CD4+ T cells as targets and effectors in the pathogenesis of primary HIV infection. / Curr HIV/AIDS Rep 2006, 3 (1) : 5鈥?2. CrossRef
  62. Zaunders JJ, Cunningham PH, Kelleher AD, Kaufmann GR, Jaramillo AB, Wright R, Smith D, Grey P, Vizzard J, Carr A, Cooper DA: Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. / J Infect Dis 1999, 180 (2) : 320鈥?29. CrossRef
  63. O'Brien SJ, Moore JP: The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. / Immunol Rev 2000, 177: 99鈥?11. CrossRef
  64. Roger M: Influence of host genes on HIV-1 disease progression. / Faseb J 1998, 12 (9) : 625鈥?32.
  65. Hazenberg MD, Hamann D, Schuitemaker H, Miedema F: T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. / Nat Immunol 2000, 1 (4) : 285鈥?89. CrossRef
  66. McCune JM: The dynamics of CD4+ T-cell depletion in HIV disease. / Nature 2001, 410 (6831) : 974鈥?79. CrossRef
  67. Alexander L, Illyinskii PO, Lang SM, Means RE, Lifson J, Mansfield K, Desrosiers RC: Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. / J Virol 2003, 77 (12) : 6823鈥?835. CrossRef
  68. Churchill MJ, Figueiredo A, Cowley D, Gray L, Purcell DF, Sullivan JS, McPhee DA, Wesselingh SL, Brew BJ, Gorry PR: Transcriptional activity of blood-and cerebrospinal fluid-derived nef/long-terminal repeat sequences isolated from a slow progressor infected with nef-deleted human immunodeficiency virus type 1 (HIV-1) who developed HIV-associated dementia. / J Neurovirol 2006, 12 (3) : 219鈥?28. CrossRef
  69. Jeeninga RE, Hoogenkamp M, Armand-Ugon M, de Baar M, Verhoef K, Berkhout B: Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. / J Virol 2000, 74 (8) : 3740鈥?751. CrossRef
  70. Gorry P, Purcell D, Howard J, McPhee D: Restricted HIV-1 infection of human astrocytes: potential role of nef in the regulation of virus replication. / Journal of Neurovirology 1998, 4 (4) : 377鈥?86. CrossRef
  71. Shioda T, Oka S, Xin X, Liu H, Harukuni R, Kurotani A, Fukushima M, Hasan MK, Shiino T, Takebe Y, Iwamoto A, Nagai Y: In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression. / J Virol 1997, 71 (7) : 4871鈥?881.
  72. Wang B, Spira TJ, Owen S, Lal RB, Saksena NK: HIV-1 strains from a cohort of American subjects reveal the presence of a V2 region extension unique to slow progressors and non-progressors. / Aids 2000, 14 (3) : 213鈥?23. CrossRef
  73. Iversen AK, Shpaer EG, Rodrigo AG, Hirsch MS, Walker BD, Sheppard HW, Merigan TC, Mullins JI: Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. / J Virol 1995, 69 (9) : 5743鈥?753.
  74. Alexander L, Aquino-DeJesus MJ, Chan M, Andiman WA: Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child. / J Virol 2002, 76 (20) : 10533鈥?0539. CrossRef
  75. Binley JM, Jin X, Huang Y, Zhang L, Cao Y, Ho DD, Moore JP: Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression. / J Virol 1998, 72 (4) : 3472鈥?474.
  76. Wang B, Ge YC, Palasanthiran P, Xiang SH, Ziegler J, Dwyer DE, Randle C, Dowton D, Cunningham A, Saksena NK: Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma. / Virology 1996, 223 (1) : 224鈥?32. CrossRef
  77. Yamada T, Iwamoto A: Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection. / Arch Virol 2000, 145 (5) : 1021鈥?027. CrossRef
  78. Michael NL, Chang G, d'Arcy LA, Ehrenberg PK, Mariani R, Busch MP, Birx DL, Schwartz DH: Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. / J Virol 1995, 69 (7) : 4228鈥?236.
  79. Hua J, Caffrey JJ, Cullen BR: Functional consequences of natural sequence variation in the activation domain of HIV-1 Rev. / Virology 1996, 222 (2) : 423鈥?29. CrossRef
  80. Smith SM, Pentlicky S, Klase Z, Singh M, Neuveut C, Lu CY, Reitz MS Jr., Yarchoan R, Marx PA, Jeang KT: An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection. / J Biol Chem 2003, 278 (45) : 44816鈥?4825. CrossRef
  81. Churchill M, Chiavaroli L, Wesselingh SL, Gorry PR: Persistence of attenuated HIV-1 rev alleles in an epidemiologically linked cohort of long-term survivors infected with nef-deleted virus. / Retrovirology 2007, 4: 43. CrossRef
  82. Adalid-Peralta L, Grangeot-Keros L, Rudent A, Ngo-Giang-Huong N, Krzysiek R, Goujard C, Deveau C, Le Gall M, Meyer L, Emilie D, Rouzioux C: Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection. / HIV Med 2006, 7 (8) : 514鈥?19. CrossRef
  83. Wilson KM, Johnson EI, Croom HA, Richards KM, Doughty L, Cunningham PH, Kemp BE, Branson BM, Dax EM: Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. / Aids 2004, 18 (17) : 2253鈥?259. CrossRef
  84. Carotenuto P, Looij D, Keldermans L, de Wolf F, Goudsmit J: Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. / Aids 1998, 12 (13) : 1591鈥?600. CrossRef
  85. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, Montefiori DC: Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. / J Infect Dis 1997, 176 (4) : 924鈥?32. CrossRef
  86. Zhang YJ, Fracasso C, Fiore JR, Bjorndal A, Angarano G, Gringeri A, Fenyo EM: Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. / J Infect Dis 1997, 176 (5) : 1180鈥?187. CrossRef
  87. Cranage MP, Whatmore AM, Sharpe SA, Cook N, Polyanskaya N, Leech S, Smith JD, Rud EW, Dennis MJ, Hall GA: Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. / Virology 1997, 229 (1) : 143鈥?54. CrossRef
  88. Enose Y, Ui M, Miyake A, Suzuki H, Uesaka H, Kuwata T, Kunisawa J, Kiyono H, Takahashi H, Miura T, Hayami M: Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. / Virology 2002, 298 (2) : 306鈥?16. CrossRef
  89. Igarashi T, Ami Y, Yamamoto H, Shibata R, Kuwata T, Mukai R, Shinohara K, Komatsu T, Adachi A, Hayami M: Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine. / J Gen Virol 1997, 78 (Pt 5): 985鈥?89.
  90. Kumar A, Mukherjee S, Shen J, Buch S, Li Z, Adany I, Liu Z, Zhuge W, Piatak M Jr., Lifson J, McClure H, Narayan O: Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus. / Virology 2002, 301 (2) : 189鈥?05. CrossRef
  91. Montefiori DC, Baba TW, Li A, Bilska M, Ruprecht RM: Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. / J Immunol 1996, 157 (12) : 5528鈥?535.
  92. Stipp HL, Kumar A, Narayan O: Characterization of immune escape viruses from a macaque immunized with live-virus vaccine and challenged with pathogenic SHIVKU-1. / AIDS Res Hum Retroviruses 2000, 16 (15) : 1573鈥?580. CrossRef
  93. Greenough TC, Somasundaran M, Brettler DB, Hesselton RM, Alimenti A, Kirchhoff F, Panicali D, Sullivan JL: Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. / AIDS Res Hum Retroviruses 1994, 10 (4) : 395鈥?03. CrossRef
  94. Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A: Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. / Nat Immunol 2006, 7 (3) : 302鈥?10. CrossRef
  95. Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, Miedema F: Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. / J Infect Dis 1998, 178 (4) : 1008鈥?018. CrossRef
  96. Riviere Y, McChesney MB, Porrot F, Tanneau-Salvadori F, Sansonetti P, Lopez O, Pialoux G, Feuillie V, Mollereau M, Chamaret S, / et al.: Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. / AIDS Res Hum Retroviruses 1995, 11 (8) : 903鈥?07. CrossRef
  97. Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, McCutchan F, Njovu L, Geis S, Hoffmann O, Maboko L, Williamson C, Birx D, Meyerhans A, Cox J, Hoelscher M: CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. / J Virol 2007, 81 (5) : 2440鈥?448. CrossRef
  98. Dyer WB, Ogg GS, Demoitie MA, Jin X, Geczy AF, Rowland-Jones SL, McMichael AJ, Nixon DF, Sullivan JS: Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. / J Virol 1999, 73 (1) : 436鈥?43.
  99. Dyer WB, Geczy AF, Kent SJ, McIntyre LB, Blasdall SA, Learmont JC, Sullivan JS: Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection. / Aids 1997, 11 (13) : 1565鈥?574. CrossRef
  100. Dyer WB, Kuipers H, Coolen MW, Geczy AF, Forrester J, Workman C, Sullivan JS: Correlates of antiviral immune restoration in acute and chronic HIV type 1 infection: sustained viral suppression and normalization of T cell subsets. / AIDS Res Hum Retroviruses 2002, 18 (14) : 999鈥?010. CrossRef
  
• 作者单位：Paul R Gorry (1) (2) (3)
  Dale A McPhee (2) (4) (6)
  Erin Verity (1) (4) (6)
  Wayne B Dyer (7) (8)
  Steven L Wesselingh (1) (2) (3)
  Jennifer Learmont (7)
  John S Sullivan (7) (8)
  Michael Roche (1)
  John J Zaunders (9)
  Dana Gabuzda (11) (12)
  Suzanne M Crowe (1) (3)
  John Mills (3) (4) (5)
  Sharon R Lewin (13) (3)
  Bruce J Brew (10)
  Anthony L Cunningham (14)
  Melissa J Churchill (1)
  
  1. Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
  2. Department of Microbiology and Immunology, University of Melbourne, Melbourne, Victoria, Australia
  3. Department of Medicine, Monash University, Melbourne, Victoria, Australia
  4. Department of Microbiology, Monash University, Melbourne, Victoria, Australia
  6. National Serology Reference Laboratory, St. Vincent's Institute for Medical Research, Fitzroy, Victoria, Australia
  7. Australian Red Cross Blood Service, Sydney, New South Wales, Australia
  8. Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia
  9. Center for Immunology, St. Vincent's Hospital, Sydney, New South Wales, Australia
  11. Dana-Farber Cancer Institute, Boston, MA, USA
  12. Department of Neurology, Harvard Medical School, Boston, MA, USA
  5. Department of Epidemiology & Community Medicine, Monash University, Melbourne, Victoria, Australia
  13. Infectious Diseases Unit, Alfred Hospital, Melbourne, Victoria, Australia
  10. Department of Neurology, St. Vincent's Hospital, Sydney, New South Wales, Australia
  14. Westmead Millennium Institute, Westmead, New South Wales, Australia
  
• ISSN：1742-4690

文摘

In efforts to develop an effective vaccine, sterilizing immunity to primate lentiviruses has only been achieved by the use of live attenuated viruses carrying major deletions in nef and other accessory genes. Although live attenuated HIV vaccines are unlikely to be developed due to a myriad of safety concerns, opportunities exist to better understand the correlates of immune protection against HIV infection by studying rare cohorts of long-term survivors infected with attenuated, nef -deleted HIV strains such as the Sydney blood bank cohort (SBBC). Here, we review studies of viral evolution, pathogenicity, and immune responses to HIV infection in SBBC members. The studies show that potent, broadly neutralizing anti-HIV antibodies and robust CD8+ T-cell responses to HIV infection were not necessary for long-term control of HIV infection in a subset of SBBC members, and were not sufficient to prevent HIV sequence evolution, augmentation of pathogenicity and eventual progression of HIV infection in another subset. However, a persistent T-helper proliferative response to HIV p24 antigen was associated with long-term control of infection. Together, these results underscore the importance of the host in the eventual outcome of infection. Thus, whilst generating an effective antibody and CD8+ T-cell response are an essential component of vaccines aimed at preventing primary HIV infection, T-helper responses may be important in the generation of an effective therapeutic vaccine aimed at blunting chronic HIV infection.